TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05138731

Intervention type: OTHER
Intervention: treatments according guidelines
Description: different group intervened with different treatment following guidelines/consensuses accordingly

Intervention type: OTHER
Intervention: treatments according guidelines
Description: different group intervened with different treatment following guidelines/consensuses accordingly

Intervention type: OTHER
Intervention: treatments according guidelines
Description: different group intervened with different treatment following guidelines/consensuses accordingly

Intervention type: OTHER
Intervention: treatments according guidelines
Description: different group intervened with different treatment following guidelines/consensuses accordingly
Study: NCT01590654

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Multiple Ascending Dose (MAD) Cohorts GS-9620
Description: This study will enroll cohorts of 6 eligible, unique subjects per cohort, randomized to either active drug or placebo (5:1) within each cohort. Subjects in Multiple Ascending Dose (MAD) Cohorts will receive GS-9620 once weekly for two weeks (QW x 2 doses).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Multiple Ascending Dose (MAD) Cohorts GS-9620
Description: This study will enroll cohorts of 6 eligible, unique subjects per cohort, randomized to either active drug or placebo (5:1) within each cohort. Subjects in Multiple Ascending Dose (MAD) Cohorts will receive GS-9620 once weekly for two weeks (QW x 2 doses).
Study: NCT02951429

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Pirfenidone
Description: Pirfenidone will be given in the range of 1602 to 2403 milligram per day (mg/day), as 3 divided doses.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pirfenidone
Description: Pirfenidone will be given in the range of 1602 to 2403 milligram per day (mg/day), as 3 divided doses.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo matched with sildenafil.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sildenafil
Description: Sildenafil will be given as 20 mg, TID.
Study: NCT02798471

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Edoxaban
Description: 15 or 30 mg tablets for participants 12 years of age to \<18, and 60 mg edoxaban suspension for oral administration to participants under 12 years of age

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Standard of Care
Description: Standard of care could include low molecular weight heparin (LMWH), vitamin K antagonist (VKA), or synthetic pentasaccharide (SP) Xa inhibitors.
Study: NCT03221361

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: thermoplastic complete denture
Description: a device used ti substitute teeth for edentlous patient made of thermoplastic resin

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: conventional acrylic resin complete denture
Description: A device used to substitute the teeth for edentlous patient made of acrylic resin
Study: NCT02044861

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PFK-158
Description: IV dose escalation
Study: NCT00971295

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: 850 mg metformin hydrochloride, once as oral single-dose and once after pre-treatment with once-daily dose of ESL 1200 mg for 6 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: 850 mg metformin hydrochloride, once as oral single-dose and once after pre-treatment with once-daily dose of ESL 1200 mg for 6 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eslicarbazepine acetate

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eslicarbazepine acetate
Study: NCT01506284

Intervention type: PROCEDURE
Intervention: Forced oscillatory technique (FOT) and laser interferometry (LIR).
Description: FOT: The stimulating signal is generated by an A/D-D/A board and amplified by a power amplifier that drives a loudspeaker the output of which is connected to inspiratory line of the ventilator. Pressure and flow are measured at the inlet of the endotracheal tube by a piezoresistive pressure transducer and a mesh-type heated pneumotachograph coupled with a differential pressure transducer.~LIR: The scanner unit is made by three laser interferometers, the beams of which are deflected on the chest wall surface by a mirror moved by a stepper motor triggered on the respiratory pattern of patient.
Study: NCT02597140

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lidocaine
Description: Patients in lidocaine group will be received an intravenous bolus injection of 1.5 mg/kg lidocaine followed by a continuous infusion of 2 mg/kg/hr lidocaine.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: normal saline
Description: Patients in control group will be received an intravenous bolus injection of 1.5 mg/kg normal saline followed by a continuous infusion of 2 mg/kg/hr normal saline.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: propofol
Description: Propofol will be administered using target controlled infusion during monitored anesthesia care to adjust 60 to 80 of bispectral index.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: propofol
Description: Propofol will be administered using target controlled infusion during monitored anesthesia care to adjust 60 to 80 of bispectral index.
Study: NCT04462965

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Toripalimab
Description: Injection,Specification 240mg/6ml, 3 mg/kg for the dose, iV, every 2 weeks a dose cycle, up to 1 year; Temozolomide: 100mg or 20mg, Every 4 weeks a dose cycle, up to 6 cycles Cisplatin: Injection, 20mg,Every 4 weeks a dose cycle, up to 6 cycles

Intervention type: COMBINATION_PRODUCT
Group type: PLACEBO_COMPARATOR
Intervention: Temozolomide
Description: Placebo：Injection,Specification 240mg/6ml, 3 mg/kg for the dose, iV, every 2 weeks a dose cycle, up to 1 year; Temozolomide: 100mg or 20mg, Every 4 weeks a dose cycle, up to 6 cycles Cisplatin: Injection, 20mg,Every 4 weeks a dose cycle, up to 6 cycles
Study: NCT04484207

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: A short video intervention
Description: Three minutes video of a veteran that shares his personal story

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: A vignette intervention
Description: A written description of the content of the video
Study: NCT03899051

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: interdental papilla reconstructive surgery with PRF
Description: Papilla reconstruction would be done with platelet rich fibrin

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: interdental papilla reconstructive surgery with subepithelial connective tissue graft
Description: Papilla reconstruction would be done with subepithelial connective tissue graft
Study: NCT00952900

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Biobehavioral
Description: 6 sessions of Biobehavioral treatment modalities that include relaxation/biofeedback, stress management, and coping skills techniques.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Active Coping/Attention Intervention
Description: 6 sessions of didactic educational techniques to expose patients to the causes of TMD, as well as introducing them to traditional treatment modalities for intervening with acute TMD problems.
Study: NCT00859157

Intervention type: PROCEDURE
Intervention: therapeutic conventional surgery
Description: Patients undergo tumescent or standard mastectomy

Intervention type: PROCEDURE
Intervention: therapeutic conventional surgery
Description: Patients undergo tumescent or standard mastectomy
Study: NCT03881904

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 0.075mg gestodene/0.03mg ethinylestradiol
Description: OCPs will be started from day 2 of the cycle preceding COH and continued for 21 days, then induction of ovulation using antagonist protocol will be started.
Study: NCT02161757

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tralokinumab
Description: Subcutaneous injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tralokinumab
Description: Subcutaneous injection

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subcutaneous injection

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subcutaneous injection
Study: NCT02588209

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Strategic Memory Advanced Reasoning Training
Description: SMART teaches strategies to improve the ability to process information.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Brain Health Workshop
Description: Brain Health Workshop provides information about brain health in a seminar format. Topics include: sleep, nutrition, and exercise.
Study: NCT01323140

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: testosterone matrix transdermal system
Study: NCT01452503

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Path Women's Condom
Description: comparison between 3 types of female condoms

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: FC2 female condom
Description: comparison between 3 types of female condoms

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Reddy 6 female condom (V-Amour)
Description: comparison between 3 types of female condoms
Study: NCT04510103

Intervention type: DRUG
Group type: OTHER
Intervention: Moisturizer A, F#9155-005
Description: OTC Monograph Drug. Used twice daily on left or right lower leg per randomization schedule.

Intervention type: DRUG
Group type: OTHER
Intervention: Moisturizer A, F#9155-005
Description: OTC Monograph Drug. Used twice daily on left or right lower leg per randomization schedule.

Intervention type: OTHER
Group type: OTHER
Intervention: Moisturizer B, F#E1387-004
Description: Cosmetic Moisturizer. Used twice daily on left or right lower leg per randomization schedule.

Intervention type: OTHER
Group type: OTHER
Intervention: Moisturizer B, F#E1387-004
Description: Cosmetic Moisturizer. Used twice daily on left or right lower leg per randomization schedule.
Study: NCT03805932

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Famotidine
Description: 20-40 mg Cycle 1, Day -2; Day 1, Day 3, Day 5. To be given 30-90 minutes prior to every moxetumomab pasudotox-tdfk infusion and is recommended every 12 hours x 2 after the end of infusion; Cycles 2-8, Day 1, Day 3, Day 5. To be given 30-90 minutes prior to every moxetumomab pasudotox-tdfk infusion and is recommended every 12 hours x 2 after the end of infusion. Pre-medications are given prior to rituximab/Ruxience on day 1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aspirin
Description: 81 mg Cycle 1, Days 1-8; Cycles 2-8, Days 1-8. Only if platelet counts ≥ 100 x 109/L.
Study: NCT04510103

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Regression
Description: 2 week regression period after 6 weeks of moisturizer use.

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Non-Regression
Description: Physical insult (tape stripping) on the lower leg after 6 weeks of moisturizer use.
Study: NCT03589222

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Selinexor
Description: Selinexor will be administered via oral at flat dose of 100 mg weekly in 4 out of each 4-week cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daratumumab
Description: daratumumab at dose of 16 mg/Kg iv weekly on days 1, 8, 15 and 22 during the first two cycles; on days 1 and 15 (Q2W) during the cycles 3 to 6; and on day 1 (Q4W) thereafter
Study: NCT01865695

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Creon
Description: Creon is a licensed product, manufactured by Abbott Laboratories, Inc. used for the therapeutic indication of pancreatic exocrine insufficiency. The route of administration is oral, with capsules being taken with main meals without chewing. The most commonly reported adverse reactions to Creon are gastrointestinal disorders of mild or moderate severity (up to 10% of patients). These include nausea, vomiting, constipation, diarrhoea and abdominal distension. An uncommon reaction (\<0.01%) of patients may develop skin reactions such as a rash or itching. No additional adverse drug reactions have been identified.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT03589222

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bortezomib
Description: bortezomib will be given via subcutaneous at dose of 1.3 mg/m2 on days 1, 8, 15 and 22 starting from the first cycle and on days 1 and 15 (Q2W) since cycle 9

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: dexamethasone is 20mg (IV) when given on days that daratumumab is administered (as pre-infusion medication) plus 20 mg of dexamethasone (VO) the day after and the dose of dexamethasone is 40mg (VO) on days when daratumumab is not administered
Study: NCT02332291

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Escitalopram
Description: Escitalopram 10-20mg daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupropion XL
Description: Bupropion XL 150-450mg daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Bupropion XL
Description: Bupropion XL 150-450mg daily
Study: NCT02376803

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Warfarin
Description: Morning vs Evening administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Warfarin
Description: Morning vs Evening administration
Study: NCT03360058

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Small Talk Big Difference Immediate access training
Description: Immediate access to 1 hour online training and supporting print materials for implementation in primary care practice

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Small Talk Big Difference delayed access training
Description: Delayed access (by 4 months) to 1 hour online training and supporting print materials for implementation in primary care practice
Study: NCT00467233

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Laser Treatment
Description: Laser treatment to half of the face at each study visit

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Acid Peel
Description: Acid peel to half of the face at each study visit
Study: NCT02690441

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive Behavioural Therapy
Description: Cognitive behavioural therapy conducted individually. 10 weekly sessions, first session lasts 90 minutes, the remaining sessions last 45 minutes.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioural Therapy
Description: Cognitive behavioural therapy conducted individually. 10 weekly sessions, first session lasts 90 minutes, the remaining sessions last 45 minutes.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical Exercise
Description: Manualised exercise. 15 weekly sessions with instructor, and two weekly unsupervised sessions performed individually.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Placebo control
Description: One follow-up telephone call à 15 minutes each week for 15 weeks. Aims to control for therapist contact in physical exercise condition and total duration of treatment.
Study: NCT02747368

Intervention type: DEVICE
Group type: OTHER
Intervention: Ocusweep system
Description: Comparison of Ocusweep system to conventional visual acuity, contrast sensitivity and visual field testing.
Study: NCT00559988

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Home Monitoring Guided OAC
Description: Active monitoring for atrial episodes through the automatic HM notifications (email, fax, short message service) is required. If the total duration over 48 consecutive hours reaches the predefined anticoagulation condition, and AF/AFL diagnosis is confirmed using the IEGM online, the site instructs the patient by telephone to start OAC. Clinicians continue to monitor patients using HM, and if freedom from AF/AFL reaches the predefined interval, stop of OAC therapy is requested over the telephone. Following stop of anticoagulation, any recurrence of AF/AFL requires restart of OAC therapy.~OAC drugs used: Dabigatran etexilate, Rivaroxaban, Warfarin, other approved VKA

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Physician-Directed OAC
Description: Patients will receive physician-directed anticoagulation therapy based on conventional criteria.~OAC drugs used: Dabigatran etexilate, Rivaroxaban, Warfarin, other approved VKA
Study: NCT01178424

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness Based Cognitive Therapy
Description: Mindfulness-Based Cognitive Therapy, a manualized, group skills training program (Segal et al., 2013) that is based on an integration of aspects of cognitive therapy for depression (Beck, 1979) with components of the mindfulness-based stress reduction program (Kabat-Zinn, 1990). Patients participate in 8 weekly sessions, each of which incorporates didactic and experiential learning, along with home practice of skills taught in the program.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive Behaviour Therapy
Description: CBT is an evidence based depression-specific psychotherapy that examines the relationship between thinking styles and the perpetuation of mood symptoms in major depression. Patients use thought records and activity scheduling, among other tools, to record and reappraise their thinking during situations where negative affect is present, both in session and for homework.
Study: NCT01032031

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Green tea + vitamin C high dose
Description: One green tea capsule (1250mg catechin) and one vitamin C tablet (100mg) daily for 3 months

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo capsule
Description: One capsule daily for 3 months
Study: NCT03286816

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: SodiumChloride

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sodium Lactate
Study: NCT02567045

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: annual FIT and colonoscopy in case of a positive test
Description: FIT and colonoscopy in case of a positive test. Annual interval (2 rounds), without diet restriction, 1 stool sample. Positive cut-off 10 mcg Hemoglobin/g feces.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: colonoscopy with sedation
Description: One-time Colonoscopy with sedation.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: colonoscopy with sedation
Description: One-time Colonoscopy with sedation.
Study: NCT04346849

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Pulpotomy
Description: Cutting the coronal portion of the pulp and application of a calcium silicate based material followed by restoration

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Pulpotomy
Description: Cutting the coronal portion of the pulp and application of a calcium silicate based material followed by restoration
Study: NCT03805932

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aspirin
Description: 81 mg Cycle 1, Days 1-8; Cycles 2-8, Days 1-8. Only if platelet counts ≥ 100 x 109/L.
Study: NCT04346849

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Pulpotomy
Description: Cutting the coronal portion of the pulp and application of a calcium silicate based material followed by restoration
Study: NCT02457949

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Non-synchronized social assistance receipt
Description: Social assistance disbursement outside government cheque issue week

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Non-synchronized social assistance receipt
Description: Social assistance disbursement outside government cheque issue week
Study: NCT05138731

Intervention type: OTHER
Intervention: treatments according guidelines
Description: different group intervened with different treatment following guidelines/consensuses accordingly

Intervention type: OTHER
Intervention: treatments according guidelines
Description: different group intervened with different treatment following guidelines/consensuses accordingly
Study: NCT01196065

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO5313534
Description: single oral dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: memantine
Description: multiple doses to steady state
Study: NCT02817386

Intervention type: OTHER
Intervention: interview
Description: Trained clinical research assistants interviewed the patients on the first and second day post surgery. The interview included the Confusion Assessment Method (CAM) and MDAS. CAM is a diagnostic algorithm used to determine the presence or absence of delirium.
Study: NCT01970527

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacological Study
Description: Correlative studies

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic Body Radiation Therapy
Description: Undergo SBRT
Study: NCT03249857

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: cognitive tasks + IQ + MINI
Description: Patients will perform different tasks:~* cognitive tasks : reaction time (Alert TEA, Zimmermann and Fimm, 2005) + Edinburgh laterality questionnaire (Oldfield,1971) + hamilton and young's scale (Tohen et al., 2009) + Montreal Cognitive Assessment (MoCA) (Nasreddine et al., 2005) + experimental task (approach/ avoidance and affordance task).~* Intelligence Quotient (IQ) test (PM38, Raven, 1960)~* Mini International Neuropsychiatric Interview (MINI, Van Vliet et al., 2006)

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: cognitive tasks
Description: Healthy volunteers will perform only the cognitive tasks = reaction time alert TEA, Zimmermann and Fimm, 2005 + Edinburgh laterality questionnaire (Oldfield, 1971) + experimental task (approach/ avoidance and affordance task).
Study: NCT04157907

Intervention type: BEHAVIORAL
Intervention: Mentalization based therapy
Description: Mentalization based therapy is a specialized treatment for patients with borderline personality disorder. The treatment program combines individual and group therapy, as well as psychoeducation
Study: NCT02671786

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MAHAN RUTF & MAHAN Vit-Min mix
Description: MAHAN RUTF dishes are locally prepared by local tribal women and each packet of RUTF provides 500-550 calories \& 15-17 gms of proteins.
Study: NCT02457949

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: cheque divided into two equal disbursements
Description: Social assistance disbursement divided into two equal payments